EUVIMEDEUVIMED entdecken
Open Access

LAMP2A gene therapy mitigates Parkinson’s disease–related pathology in nonhuman primates

Marie-Laure Arotcarena iD, Maria Fouka, Elena G Gialinaki, Marianna Giannopoulou, Hugo Jadot iD, Morgane Darricau, Anna Lovisotto, Sandra Dovero iD, Vincent Planche iD, Elio Balpe, Melyna Achour, Marie-Laure Thiolat iD und 13 weitere

Science Advances · 30.10.2026 · 12 (44)

DOI: 10.1126/sciadv.aeg1787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 30.10.2026. Verfasst von Marie-Laure Arotcarena und 24 weiteren Autor:innen. Beteiligte Einrichtung: Univ. de Bordeaux, CNRS, IMN, UMR 5293, F-33000 Bordeaux, France. Hauptthemen laut MEDLINE: Lysosomal-Associated Membrane Protein 2, Parkinson Disease, Genetic Therapy. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Parkinson's Disease Foundation, Fondation pour la Recherche Médicale, Lundbeckfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chaperone-mediated autophagy (CMA), regulated by its lysosomal receptor LAMP2A, is a key pathway for αSynuclein (αSyn) clearance and a direct target of αSyn-related neurotoxicity. Rodent studies show that LAMP2A enhancement reverses neurodegeneration, whereas its deficiency accelerates pathology. To test translational relevance, we examined whether increasing LAMP2A expression in nonhuman primates could mitigate α-synucleinopathy induced by injections of Parkinson’s disease patient-derived Lewy body (LB) extract. Increasing LAMP2A expression protected nigral dopaminergic neurons from LB-induced αSyn neurodegeneration, delayed the formation and release of pathology-related αSyn species, and evoked a beneficial effect on motor behavior and on cognitive functions of the primate model. Our findings provide preliminary preclinical evidence supporting CMA enhancement as a therapeutic strategy for αSynucleinopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lysosomal-Associated Membrane Protein 2Parkinson DiseaseGenetic TherapyAnimalsalpha-SynucleinHumansDopaminergic NeuronsDisease Models, AnimalLewy BodiesAutophagyGene Therapy Agents

Substanzen

Lysosomal-Associated Membrane Protein 2alpha-Synuclein

Autor:innen und Institutionen

  • Univ. de Bordeaux, CNRS, IMN, UMR 5293, F-33000 Bordeaux, France.
  • Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 4, Soranou Efesiou Street, Athens 11527, Greece.
  • Motac Neuroscience, F-33000 Bordeaux, France.
  • Neuron Experts SAS, F-13015 Marseille, France.
  • Brain Repair and Imaging in Neural Systems (B.R.A.I.N.S) Unit, Department of Experimental Medical Science, Lund University, BMC D11, 22184 Lund, Sweden.
  • DANDRITE-Danish Research Institute of Translational Neuroscience and Department of Biomedicine, University of Aarhus, Aarhus C, Denmark.

ORCID-Profile: Marie-Laure Arotcarena, Hugo Jadot, Sandra Dovero, Vincent Planche, Marie-Laure Thiolat, Nathalie Dutheil, Qin Li, Emilie Noe, Karim Harhouri, Deniz Kirik, Nanna M Jensen, Poul H Jensen, Leonidas Stefanis, Erwan Bezard, Benjamin Dehay, Maria Xilouri

Förderung

  • Parkinson's Disease Foundation
  • Fondation pour la Recherche Médicale
  • Lundbeckfonden
  • Université de Bordeaux
  • Foundation for Research and Technology-Hellas
  • Michael J. Fox Foundation
  • European Union-Next Generation EU, Greece 2.0 National Recovery and Resilience Plan Flagship program
  • ERDYS

Zitieren

APA

Arotcarena, M. L., Fouka, M., Gialinaki, E. G., Giannopoulou, M., Jadot, H., Darricau, M., Lovisotto, A., Dovero, S., Planche, V., Balpe, E., Achour, M., Thiolat, M. L., Dutheil, N., Li, Q., Noe, E., Pioli, E. Y., Harhouri, K., Steinschneider, R., Kirik, D., …, & Xilouri, M. (2026). LAMP2A gene therapy mitigates Parkinson’s disease–related pathology in nonhuman primates. Science Advances, 12(44). https://doi.org/10.1126/sciadv.aeg1787

Vancouver

Arotcarena ML, Fouka M, Gialinaki EG, Giannopoulou M, Jadot H, Darricau M, et al. LAMP2A gene therapy mitigates Parkinson’s disease–related pathology in nonhuman primates. Science Advances. 2026;12(44). doi:10.1126/sciadv.aeg1787

BibTeX
@article{Arotcarena2026,
  author = {Arotcarena, Marie-Laure and Fouka, Maria and Gialinaki, Elena G and Giannopoulou, Marianna and Jadot, Hugo and Darricau, Morgane and Lovisotto, Anna and Dovero, Sandra and Planche, Vincent and Balpe, Elio and Achour, Melyna and Thiolat, Marie-Laure and Dutheil, Nathalie and Li, Qin and Noe, Emilie and Pioli, Elsa Y and Harhouri, Karim and Steinschneider, Rémy and Kirik, Deniz and Jensen, Nanna M and Jensen, Poul H and Stefanis, Leonidas and Bezard, Erwan and Dehay, Benjamin and Xilouri, Maria},
  title = {LAMP2A gene therapy mitigates Parkinson’s disease–related pathology in nonhuman primates},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {44},
  doi = {10.1126/sciadv.aeg1787}
}
Kostenlos starten →